Inhibikase Therapeutics is pioneering innovative small-molecule kinase inhibitor therapeutics aimed at treating Parkinson's disease and related neurodegenerative disorders. Central to their approach is the RAMP™ (Re-engineering Approach with Metabolism Preserved) Drug Innovation Engine, which allows the company to design novel medications by leveraging insights from existing clinically evaluated drugs. This technology focuses on modifying the chemical structure of known kinase inhibitors to enhance their safety profiles and pharmacological properties, thereby creating first-in-class therapies that can potentially alter the course of neurodegenerative diseases. The RAMP™ engine is particularly significant in developing treatments that target the underlying mechanisms of diseases like Parkinson's, rather than merely alleviating symptoms.

Inhibikase is also advancing its prodrug technology, which enhances drug delivery and minimizes common side effects associated with kinase inhibitors, such as gastrointestinal disturbances. Their lead candidate, Risvodetinib (IkT-148009), is a selective oral c-Abl kinase inhibitor that has shown promise in halting disease progression and promoting functional recovery in preclinical models of Parkinson's disease. This innovative approach not only aims to address the core pathological processes of neurodegeneration but also seeks to provide safer and more effective treatment options for patients suffering from these debilitating conditions.

United States

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Cancer

Central Nervous System (CNS)

Digestive System Diseases

Hematologic Diseases

Infectious Diseases

Nervous System Diseases

Pharyngeal Diseases

Psychological Diseases

Inhibikase Therapeutics

Chronic myelogenous leukemia

IkT-001Pro

Small Molecule Pharmaceuticals

Gastric cancer

Hematologic malignancies

<p class="font_8">IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec®). Imatinib is commonly taken for hematological and gastrointestinal cancers that arise from Abl kinase mutations found in the bone marrow or for gastrointestinal cancers that arise from c-Kit and/or PDGFRa/b mutations in the stomach; c-Kit, PDGFRa/b and Abl are all members of the Abelson Tyrosine Kinase protein family. IkT-001Pro has the potential to be a safer alternative for patients and may improve the number of patients that reach and sustain major and/or complete cytogenetic responses in stable-phase CML and/or reduce the relapse rate for these patients. In preclinical studies, IkT-001Pro was shown to be as much as 3.4 times safer than imatinib in non-human primates, reducing burdensome gastrointestinal side effects that occur following oral administration. Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for stable-phase CML in September, 2018.</p>

Dysphagia

Neurogenic Constipation

Parkinson's disease

Risvodetinib (ikT-148009)

Pulmonary arterial hypertension

The active ingredient in IkT-001, imatinib, has previously been shown to be disease-modifying for PAH.

IkT-001

Multiple System Atrophy

Risvodetinib (IkT-148009)

Dementia

IkT-148x

Progressive Multifocal Leukoencephalopathy

IkT-01427

Neurodegenerative disease

<p class="font_8">Risvodetinib (IkT-148009), is a potent, selective small-molecule medication designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. Risvodetinib (IkT-148009) is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.</p>

Georgia

Vaccines

Therapeutic

Inhibikase Therapeutics

Company Details